Trials / Completed
CompletedNCT02326441
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Athenex, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of the study drug KX2-361 and to determine how much of the study drug enters the bloodstream, in patients with advanced malignancies that have not responded to conventional therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KX2-361 |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-07-01
- Completion
- 2018-05-23
- First posted
- 2014-12-29
- Last updated
- 2019-01-15
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02326441. Inclusion in this directory is not an endorsement.